Personalized Medicine Bulletin The source for business, legal, and regulatory developments shaping an evolving industry

Tag Archives: Genetic Tests

China Issues Human Genetic Resources Management Regulations

Posted in Personalized Medicine; Uncategorized

Those seeking to conduct research involving human genetic material within the People’s Republic of China or to import into China such material should review China’s recently issued draft regulations (“Draft”) for the management of its human genetic resources. The regulations apply to the collection, preservation, research, development, immigration and other activities involving human genetic material.

The Draft provides provides that only legal entities established by law in China may engage in the collection and preservation of human genetic material. Foreign entities can conduct research with the cooperation of a Chinese entity. Such cooperation shall be subject to the approval of Ministry of Science and Technology of P.R.C (MOST). In addition, the foreign entity shall ensure that staff from the Chinese entity take part in the substantive research and development activity during the collaboration. Though the Draft does not provide that the Chinese party will retain title to any intellectual property developed from the collaboration, the Chinese entity is required to provide a report to MOST regarding the research and development activities within three months from the ending of the international cooperation. The Draft allows the ownership of intellectual property generated from the collaboration to be decided by agreement between the Chinese and foreign entities.  

The Draft also notes that the export of human genetic resource sourced from the territory of China shall be subject to the approval of MOST. Because the Draft prohibits trading of human genetic resources, the foreign receiving unit must be the foreign party to the international cooperation approved by MOST. Human genetic resource material imported into China shall be registered with MOST.  

A copy of the Draft Regulation on Human Genetic Resources 2012 is attached.

Special thanks to Foley & Lardner’s Max Lin for summarizing the Draft regulations. Max is resident in Foley’s Shanghai office.

Fed. Cir. Denies Myriad’s Petition for Rehearing in Gene Patenting Case

Posted in Gene Patents; Genetic Testing

We previously reported that the ACLU and Myriad each filed a Petition for Panel Rehearing with the Federal Circuit for review of the July 29, 2011 decision, Assn. Molec. Path. et al. v. USPTO et al. This dispute, now known as the “gene patenting case,” reviewed whether isolated genetic material and diagnostic tests that rely on the screening of this material are patent-eligible. Our prior posts discuss the merits of the July 29th, 2011 decision.

On September 13, 2011, the Federal Circuit denied the ACLU’spetition for rehearing. Today, we report that on September 16, 2011, the Federal Circuit denied Myriad’s petition as well.

Subject Matter Jurisdiction Challenged in Supreme Court’s Review of Mayo v. Prometheus

Posted in Companion Diagnostics; Gene Patents; Genetic Testing

An international intellectual property association filed an amicus curie brief urging the U.S Supreme Court to dismiss the dispute and issue presented in Mayo Collaborative Services v. Prometheus Laboratories, Inc., 131 S.Ct. 3027 (2011), arguing that the district court and Federal Circuit lacked subject matter jurisdiction. The amici argued that for reasons that are not clear, the district court and the Federal Circuit unapplied, misapplied, or simply overlooked Congress’ legislative efforts to achieve a globally-desired limitation of exclusive patent rights.

Continue reading this entry